Related Experiment Videos
Hepatotoxicity due to lysine salt of bendazac
M Alcalde1, M Garcia-Diaz, F Najarro
1Gastroenterology Dept. Infanta Cristina University Hospital, University of Extremadura, Badajoz, Spain.
Scandinavian Journal of Gastroenterology
|February 1, 1996
Abstract
Background:
The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine.
Methods:
Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease.
Results:
Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1).
Conclusions:
Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.